ORIGINAL RESEARCH article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1631448
This article is part of the Research TopicGenetic and Immunological Insights into Angioedema Without WhealsView all 10 articles
Disease control and disease activity in hereditary angioedema: two sides of the same coin?
Provisionally accepted
- University of Alberta, Edmonton, Canada
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Hereditary angioedema (HAE) is a genetic disorder characterized by episodic subcutaneous and submucosal swelling. Patient-reported outcome measures (PROMs) are recommended for routine clinical assessment by international guidelines and are used as secondary outcome measures in pivotal clinical trials for novel investigational drugs. The Angioedema Control Test (AECT) and Hereditary Angioedema Activity Score (HAE-AS) are validated tools designed to aid in HAE patient assessment, but the extent to which they measure different disease outcomes is unclear. The aim of this study was to examine how these measures correlate and inform clinical practice.We conducted a retrospective study of patients with HAE types 1 and 2 at the Edmonton Angioedema Center of Reference and Excellence. AECT and HAE-AS scores were obtained from patient-completed questionnaires during routine visits. Multiple linear regression was used to examine the association between HAE-AS and AECT scores with age, sex, and long-term prophylaxis (LTP) status as predictors. Receiver operating characteristic (ROC) analysis was used to determine the optimal HAE-AS score cutoff that predicts poor disease control as determined by the AECT.Results: There were 25 participants included with a mean age of 39.4 years (SD = 13.7), 72% of whom were female. Most had HAE Type 1 (76%) and 52% were receiving LTP. SC C1-inhibitor therapy was the most common LTP (36%). Most had well managed disease with a median AECT score of 11.88 (range: 5-16) and HAE-AS of 5.84 (range: 0-13). A statistically significant but weak negative correlation was found between AECT and HAE-AS (β=-0.67, p=0.002). ROC analysis showed that an HAE-AS score >5 had a sensitivity of 100% and specificity of 61% for poor disease control.The AECT and HAE-AS instruments are weakly correlated, indicating that they provide related but distinct information to the practicing clinician. Using both AECT and HAE-AS in clinical practice can thus provide a more comprehensive patient evaluation.
Keywords: hereditary angioedema, C1 Inhibitor, Patient Reported Outcomes, immunodeficiency, Angioedema
Received: 19 May 2025; Accepted: 10 Jul 2025.
Copyright: © 2025 Heibati, Borle, Ritchie and Adatia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Adil Adatia, University of Alberta, Edmonton, Canada
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.